CELU Stock Overview
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Celularity Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.21 |
| 52 Week High | US$8.90 |
| 52 Week Low | US$1.59 |
| Beta | 0.30 |
| 1 Month Change | -39.09% |
| 3 Month Change | -7.76% |
| 1 Year Change | -49.47% |
| 3 Year Change | -96.83% |
| 5 Year Change | n/a |
| Change since IPO | -96.72% |
Recent News & Updates
Recent updates
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%
Feb 14
Celularity appoints Adrian Kilcoyne as chief medical officer
Oct 03Celularity falls after announcing fund raising deal
Sep 15Celularity falls 10% on deal for $150M common stock offering
Sep 08Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers
Jul 27News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts
Dec 14Celularity: Celgene Spin-Off Developing Allogeneic Therapies
Sep 06Shareholder Returns
| CELU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.0% | 1.5% | 1.2% |
| 1Y | -49.5% | 1.1% | 24.7% |
Return vs Industry: CELU underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: CELU underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| CELU volatility | |
|---|---|
| CELU Average Weekly Movement | 19.6% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CELU's share price has been volatile over the past 3 months.
Volatility Over Time: CELU's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 225 | Bob Hariri | www.celularity.com |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company’s lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease.
Celularity Inc. Fundamentals Summary
| CELU fundamental statistics | |
|---|---|
| Market cap | US$69.92m |
| Earnings (TTM) | -US$181.41m |
| Revenue (TTM) | US$14.79m |
4.7x
P/S Ratio-0.4x
P/E RatioIs CELU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELU income statement (TTM) | |
|---|---|
| Revenue | US$14.79m |
| Cost of Revenue | US$11.65m |
| Gross Profit | US$3.13m |
| Other Expenses | US$184.54m |
| Earnings | -US$181.41m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.33 |
| Gross Margin | 21.19% |
| Net Profit Margin | -1,226.72% |
| Debt/Equity Ratio | 115.7% |
How did CELU perform over the long term?
See historical performance and comparison